These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Ha YC; Cho MR; Park KH; Kim SY; Koo KH Clin Orthop Relat Res; 2010 Dec; 468(12):3393-8. PubMed ID: 20865463 [TBL] [Abstract][Full Text] [Related]
4. Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy-a long-term radiological follow-up. Png MA; Mohan PC; Koh JSB; Howe CY; Howe TS Osteoporos Int; 2019 Dec; 30(12):2417-2428. PubMed ID: 31435684 [TBL] [Abstract][Full Text] [Related]
5. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Lenart BA; Neviaser AS; Lyman S; Chang CC; Edobor-Osula F; Steele B; van der Meulen MC; Lorich DG; Lane JM Osteoporos Int; 2009 Aug; 20(8):1353-62. PubMed ID: 19066707 [TBL] [Abstract][Full Text] [Related]
6. Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy. Porrino JA; Kohl CA; Taljanovic M; Rogers LF AJR Am J Roentgenol; 2010 Apr; 194(4):1061-4. PubMed ID: 20308511 [TBL] [Abstract][Full Text] [Related]
8. Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Banffy MB; Vrahas MS; Ready JE; Abraham JA Clin Orthop Relat Res; 2011 Jul; 469(7):2028-34. PubMed ID: 21350886 [TBL] [Abstract][Full Text] [Related]
9. Sensitivity and specificity of radiographic characteristics in atypical femoral fractures. Adams AL; Xue F; Chantra JQ; Dell RM; Ott SM; Silverman S; Giaconi JC; Critchlow C Osteoporos Int; 2017 Jan; 28(1):413-417. PubMed ID: 27766369 [TBL] [Abstract][Full Text] [Related]
10. A Scapular Spine Fracture Defined on the Basis of a Bisphosphonate: a Case Report and Review of the Literature. Ilyas G; Senyuva G Acta Chir Orthop Traumatol Cech; 2022; 89(4):312-314. PubMed ID: 36055673 [TBL] [Abstract][Full Text] [Related]
11. The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates. Sato H; Kondo N; Wada Y; Nakatsue T; Iguchi S; Fujisawa J; Kazama JJ; Kuroda T; Nakano M; Endo N; Narita I Osteoporos Int; 2016 Mar; 27(3):1217-1225. PubMed ID: 26519417 [TBL] [Abstract][Full Text] [Related]
12. High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates. Sato H; Kondo N; Nakatsue T; Wada Y; Fujisawa J; Kazama JJ; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I Osteoporos Int; 2017 Aug; 28(8):2367-2376. PubMed ID: 28409215 [TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-associated fractures of the femur: pathophysiology and treatment. Einhorn TA; Bogdan Y; Tornetta P J Orthop Trauma; 2014 Jul; 28(7):433-8. PubMed ID: 24121986 [No Abstract] [Full Text] [Related]
14. [Atypical femoral fracture associated with the use of bisphosphonates, an adverse drug reaction not to be missed]. Ing Lorenzinit K; Meier R; Suva D; Dayer P; Desmeules J; Peter R Rev Med Suisse; 2012 Jun; 8(344):1238-42. PubMed ID: 22730621 [TBL] [Abstract][Full Text] [Related]